Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
627 clinical trials found
Clinical trials

CJSB462B12201

A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) (NCT07047118)

This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
Currently recruiting

CL1-95035-001

A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP (NCT06188702)

Currently recruiting

CLB-4000-1-001

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B (ACTRN12625000204448)

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B
Currently recruiting

CLEOPATTRA

CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy [ATTR-CM] (NCT07207811)

This study aims to determine whether a new medication, NNC6019-0001, can lower the risk of heart-related complications in people diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease that affects the heart. Participants will be randomly assigned to receive either NNC6019-0001 or a placebo, which contains no active drug. Throughout the study, all participants will continue their standard heart treatments as advised by their healthcare provider.
Coming soon

CLN-619-001

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (NCT05117476)

Currently recruiting

CLOU064C12306

A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib (NCT06846281)

Currently recruiting

CLOU064J12301

A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa (NCT06799000)

Currently recruiting

CLOU064M12301

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines (NCT05976243)

No longer recruiting

CMBG453E12101

A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome (NCT04810611)

Currently recruiting

CML14 ASCENDENCE

ASCENDANCE - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic Etiology (ACTRN12623001338651)

At the start of the trial, Patients will have genetic testing and all patients will then receive treatment with Asciminib monotherapy at 80mg daily for the first four weeks, while the genetic results are analysed. Patients are then split into high or standard risks groups based on their genetic results. Patients determined to be at standard risk will continue to receive 80mg daily Asciminib monotherapy while high risk patients will receive combination therapy of: 80mg of Asciminib daily and 50mg of Dasatinib daily. Overall treatment duration is upto 2 years.
Currently recruiting

COALA Study

COALA Trial: Changing Outcomes After Low Anterior resection in colorectal cancer by anal sphincter prehabilitation prior to reversal of ileostomy – a parallel explanatory (COALA-1) and pragmatic trial (COALA-2) (Trial registration pending)

Currently recruiting

COALITION

A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL) (COALITION) (NCT04914741)

No longer recruiting

COBRRA

COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism (COBRRA) (NCT03266783)

Currently recruiting

Codebreak-202 20190341

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (NCT05920356)

Currently recruiting

Cognition in Progressive Supranuclear Palsy

Assessing cognitive trajectories in Progressive Supranuclear Palsy using remote computerized reaction time tasks (Trial Not Registered)

This study aims to assess the potential role for remote computerised cognitive battery measurements in detecting short-term cognitive decline in PSP, and to explore its role as a novel biomarker for disease progression in descriptive and therapeutic clinical trials.

Currently recruiting

COLLIGO

mavaCamten Observational evidence Global cOnsortium in HCM [COLLIGO-HCM] (NCT06372457)

The aim of this study is to investigate treatments and real-world effectiveness for hypertrophic cardiomyopathy (HCM), including examining the path to diagnosis, disease progression, and the new treatment for obstructive HCM (o-HCM), mavacamten. This protocol localisation for COLLIGO-HCM is for The Alfred Hospital participating site in Australia. It will address only a subset of the objectives from the master protocol which were deemed applicable after conducting feasibility.

No longer recruiting

COMB157GAU01

Secondary use of data study characterizing Kesimpta (ofatumumab) onboarding and utilization in RMS patients using MSGo, with a non-interventional primary use of data sub-study comparing Patient Reported Outcomes relative to Clinical Outcomes (EAFToS) (NCT05090033)

No longer recruiting

CORE

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (NCT05079919)

No longer recruiting

CorSky

BIO|CONCEPT.CorSky Family (NCT05610176)

No longer recruiting

CorWave

A Clinical Study of the CorWave® Left Ventricular Assist System For the treatment of patients with advanced heart failure (NCT06907017)

The study is a prospective, multi-center, non-randomized trial to evaluate the safety and effectiveness of the CorWave LVAS for the treatment of advanced heart failure patients. Trial aim: implantation and use of the CorWave LVAS to evaluate the safety and effectiveness of the CorWave LVAD to treat advanced left ventricular heart failure.
Currently recruiting
7 8 9 10 11